Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolvaptan and Octreotide LAR in ADPKD (TOOL)
NCT03541447Phase 2Completed
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Dec 2018
- Primary completion
- Dec 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of octreotide in autosomal dominant polycystic kidney disease (ADPKD), sponsored by Mario Negri Institute for Pharmacological Research. Started Dec 2018; status: completed.
02
Drugs
octreotide
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT03541447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03541447.